SCHEMBL16399485

SCHEMBL16399485

[CH2]S(=O)(=O)C(C)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
ALDH1A1 P00352 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GMNN O75496 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
PMP22 Q01453 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP2C19 P33261 1/20 0.41
SRC P12931 1/20 0.39
TAAR1 Q96RJ0 2/20 0.38
TRPA1 O75762 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
XBP1 P17861 1/20 0.38
ATM Q13315 1/20 0.38
HSD11B1 P28845 1/20 0.37
ADRA2A P08913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020687 0.80 ALDH1A1 (0.44) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL4450989 0.80 ALDH1A1 (0.44) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL11846946 0.80 ALDH1A1 (0.44) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL369243 0.80 ALDH1A1 (0.44) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL25518782 0.78 ALDH1A1 (0.42) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL6725173 0.78 ALDH1A1 (0.42) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL18028833 0.76 PTGES2 (0.44) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL894171 0.76 ALDH1A1 (0.42) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL3398714 0.76 SRC (0.54) LMNAALDH1A1NPSR1MAPTKDM4E
SCHEMBL248500 0.76 SRC (0.54) LMNAALDH1A1NPSR1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 LMNA 4192/4885ALDH1A1 1611/4885NPSR1 3939/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 LMNA 4192/4885ALDH1A1 1611/4885NPSR1 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.